Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Two biotech firms pare staff
November 6, 2006
| A version of this story appeared in
Volume 84, Issue 45
Critical Therapeutics is cutting 63 positions, more than half its workforce, as it focuses on commercializing the controlled-release form of zileuton for the treatment of asthma. Among the eliminated jobs are 20 in R&D and 32 in the sales and marketing of standard zileuton, sold as Zyflo. Meanwhile, QLT is eliminating about 80 jobs in response to a continued decline in sales of Visudyne, its treatment for age-related macular degeneration. QLT employed 438 people as of March 1.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter